Dupixent® (dupilumab) approved by fda as the first and only treatment indicated for prurigo nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-phase 3 program consisting of two pivotal trials about 75,000 adults in the u.s. living with prurigo nodularis are most in need of new treatment options approval represents the second dermatology indication for dupixent and fifth disease indication overall in the u.s. tarrytown, n.y. and paris , sept.
REGN Ratings Summary
REGN Quant Ranking